Key issues concerning fungistatic versus fungicidal drugs

被引:47
作者
Graybill, JR
Burgess, DS
Hardin, TC
机构
[1] UNIV TEXAS, HLTH SCI CTR, DEPT PHARMACOL, SAN ANTONIO, TX 78284 USA
[2] AUDIE L MURPHY MEM VET ADM MED CTR, MED SERV, INFECT DIS SECT, SAN ANTONIO, TX 78284 USA
[3] UNIV TEXAS, COLL PHARM, AUSTIN, TX 78712 USA
关键词
D O I
10.1007/BF01575120
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Are there any fungicidal drugs available today? A critical issue in answering this question is that of definition. The simplest, most stringent definitions identify fungistatic drugs as those that inhibit growth, whereas fungicidal drugs kill fungal pathogens. The immunocompetent host is usually far better equipped to eliminate fungal pathogens than the immunosuppressed host. Therefore, it would be especially desirable to have a truly fungicidal drug, one that absolutely kills all fungi, as a treatment option for the immunosuppressed patient. The critical question would be whether a fungicidal drug can be delivered to the target site in a concentration high enough for a sufficient time to reduce the intralesional fungal counts to zero. By this simple definition, there are no fungicidal drugs available today. However, an accepted alternative definition is that often used by the bacteriologist: Fungicidal drugs are those that lead to a reduction of 99.9% of the initial inocula. Although this less restrictive in vitro standard is more easily met, it has serious limitations. Whether the 99.9% kill should be an acceptable standard remains uncertain. As an alternative, the minimum inhibitory concentration, though indicating static activity, has served well; perhaps it should be the only information reported for fungal susceptibility testing.
引用
收藏
页码:42 / 50
页数:9
相关论文
共 61 条
[1]   EVALUATION OF WATER-SOLUBLE PNEUMOCANDIN ANALOGS L-733560, L-705589, AND L-731373 WITH MOUSE MODELS OF DISSEMINATED ASPERGILLOSIS, CANDIDIASIS, AND CRYPTOCOCCOSIS [J].
ABRUZZO, GK ;
FLATTERY, AM ;
GILL, CJ ;
KONG, L ;
SMITH, JG ;
KRUPA, D ;
PIKOUNIS, VB ;
KROPP, H ;
BARTIZAL, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) :1077-1081
[2]   COMBINED THERAPY WITH FLUCONAZOLE AND FLUCYTOSINE IN MURINE CRYPTOCOCCAL MENINGITIS [J].
ALLENDOERFER, R ;
MARQUIS, AJ ;
RINALDI, MG ;
GRAYBILL, JR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (04) :726-729
[3]   CORRELATION BETWEEN IN-VITRO AND IN-VIVO ACTIVITY OF ANTIFUNGAL AGENTS AGAINST CANDIDA SPECIES [J].
ANAISSIE, EJ ;
KARYOTAKIS, NC ;
HACHEM, R ;
DIGNANI, MC ;
REX, JH ;
PAETZNICK, V .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (02) :384-389
[4]   IN-VITRO EVALUATION OF THE PNEUMOCANDIN ANTIFUNGAL AGENT L-733560, A NEW WATER-SOLUBLE HYBRID OF L-705589 AND L-731373 [J].
BARTIZAL, K ;
SCOTT, T ;
ABRUZZO, GK ;
GILL, CJ ;
PACHOLOK, C ;
LYNCH, L ;
KROPP, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) :1070-1076
[5]   INVITRO ANTIFUNGAL ACTIVITIES AND INVIVO EFFICACIES OF 1,3-BETA-D-GLUCAN SYNTHESIS INHIBITORS L-671,329, L-646,991, TETRAHYDROECHINOCANDIN-B, AND L-687,781, A PAPULACANDIN [J].
BARTIZAL, K ;
ABRUZZO, G ;
TRAINOR, C ;
KRUPA, D ;
NOLLSTADT, K ;
SCHMATZ, D ;
SCHWARTZ, R ;
HAMMOND, M ;
BALKOVEC, J ;
VANMIDDLESWORTH, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (08) :1648-1657
[6]   COMPARISON OF AMPHOTERICIN-B ALONE AND COMBINED WITH FLUCYTOSINE IN THE TREATMENT OF CRYPTOCCAL MENINGITIS [J].
BENNETT, JE ;
DISMUKES, WE ;
DUMA, RJ ;
MEDOFF, G ;
SANDE, MA ;
GALLIS, H ;
LEONARD, J ;
FIELDS, BT ;
BRADSHAW, M ;
HAYWOOD, H ;
MCGEE, ZA ;
CATE, TR ;
COBBS, CG ;
WARNER, JF ;
ALLING, DW .
NEW ENGLAND JOURNAL OF MEDICINE, 1979, 301 (03) :126-131
[7]   AZOLE DRUG-RESISTANCE AS A CAUSE OF CLINICAL RELAPSE IN AIDS PATIENTS WITH CRYPTOCOCCAL MENINGITIS [J].
BIRLEY, HDL ;
JOHNSON, EM ;
MCDONALD, P ;
PARRY, C ;
CAREY, PB ;
WARNOCK, DW .
INTERNATIONAL JOURNAL OF STD & AIDS, 1995, 6 (05) :353-355
[8]   ROLE OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AS ADJUVANT THERAPY FOR FUNGAL INFECTION IN PATIENTS WITH CANCER [J].
BODEY, GP ;
ANAISSIE, E ;
GUTTERMAN, J ;
VADHANRAJ, S .
CLINICAL INFECTIOUS DISEASES, 1993, 17 (04) :705-707
[9]   A PLACEBO-CONTROLLED TRIAL OF MAINTENANCE THERAPY WITH FLUCONAZOLE AFTER TREATMENT OF CRYPTOCOCCAL MENINGITIS IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
BOZZETTE, SA ;
LARSEN, RA ;
CHIU, J ;
LEAL, MAE ;
JACOBSEN, J ;
ROTHMAN, P ;
ROBINSON, P ;
GILBERT, G ;
MCCUTCHAN, JA ;
TILLES, J ;
LEEDOM, JM ;
RICHMAN, DD .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (09) :580-584
[10]   SUSCEPTIBILITIES OF SERIAL CRYPTOCOCCUS-NEOFORMANS ISOLATES FROM PATIENTS WITH RECURRENT CRYPTOCOCCAL MENINGITIS TO AMPHOTERICIN-B AND FLUCONAZOLE [J].
CASADEVALL, A ;
SPITZER, ED ;
WEBB, D ;
RINALDI, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (06) :1383-1386